- Home
- IMUX vs STEM Comparison
IMUX vs STEM Comparison
Compare IMUX & STEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- STEM
- Stock Information
- Founded
- IMUX 2016
- STEM 2009
- Country
- IMUX United States
- STEM United States
- Employees
- IMUX N/A
- STEM N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- STEM Computer Software: Prepackaged Software
- Sector
- IMUX Health Care
- STEM Technology
- Exchange
- IMUX Nasdaq
- STEM Nasdaq
- Market Cap
- IMUX 100.0M
- STEM 100.2M
- IPO Year
- IMUX N/A
- STEM N/A
- Fundamental
- Price
- IMUX $1.07
- STEM $1.22
- Analyst Decision
- IMUX Strong Buy
- STEM Hold
- Analyst Count
- IMUX 6
- STEM 8
- Target Price
- IMUX $12.67
- STEM $1.38
- AVG Volume (30 Days)
- IMUX 885.0K
- STEM 17.6M
- Earning Date
- IMUX 02-20-2025
- STEM 02-26-2025
- Dividend Yield
- IMUX N/A
- STEM N/A
- EPS Growth
- IMUX N/A
- STEM N/A
- EPS
- IMUX N/A
- STEM N/A
- Revenue
- IMUX N/A
- STEM $256,183,000.00
- Revenue This Year
- IMUX N/A
- STEM N/A
- Revenue Next Year
- IMUX N/A
- STEM $140.17
- P/E Ratio
- IMUX N/A
- STEM N/A
- Revenue Growth
- IMUX N/A
- STEM N/A
- 52 Week Low
- IMUX $0.97
- STEM $0.30
- 52 Week High
- IMUX $2.11
- STEM $3.80
- Technical
- Relative Strength Index (RSI)
- IMUX 45.08
- STEM 82.05
- Support Level
- IMUX $0.99
- STEM $0.56
- Resistance Level
- IMUX $1.09
- STEM $0.88
- Average True Range (ATR)
- IMUX 0.06
- STEM 0.13
- MACD
- IMUX -0.00
- STEM 0.08
- Stochastic Oscillator
- IMUX 39.89
- STEM 100.00
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About STEM Stem Inc.
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on innovative technology services that transform the way energy is distributed and consumed.